Question for written answer E-003831/2019
to the Commission
Rule 138
Susanna Ceccardi (ID)

Subject: Details regarding the works at the European Medicines Agency

The aim of the European Medicines Agency (EMA) is to protect and promote the health of people and animals by assessing and monitoring medicinal products within the European Union (EU) and the European Economic Area (EEA).

Because of Brexit, on 20 November 2017, by secret vote of the Council of the European Union, the city of Amsterdam was selected as the location for the EMA headquarters, after running neck and neck with Milan. The agency was transferred from London to the Netherlands in March 2019, to a temporary location until the final building was ready.

On 29 January 2018, the Executive Director of EMA admitted that the completion of the new Agency building would be delayed.

The Italian Government and the Municipality of Milan appealed, but the European Union confirmed Amsterdam as its headquarters, provided that the entire move was completed by November 2019.

In view of this, can the Commission answer the following questions:

1. In the light of these delays, would it be possible to make all the information concerning the Netherlands application transparent?

2. Has it checked the precise state of play of the work, which might enable the new EMA headquarters to be used?

3. Should there be any further delays in the work schedule, does the Commission plan to set a new deadline?